在小细胞肺癌中,支链酶体抑制会诱导Z-RNA和ZBP1驱动的细胞死亡
Xinpei Jiang1, Xueying Ma2, Yunyun Zhou3
1Nuclear Dynamics and Cancer Program, Fox Chase Cancer Center, Philadelphia, PA, USA; Cancer Epigenetics Institute, Fox Change Cancer Center, Philadelphia, PA, USA; Center for Immunology, Fox Chase Cancer Center, Philadelphia, PA, USA; Biomedical Science Graduate Program, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA.
Cell reports
|October 5, 2025
概括
支链酶体抑制剂触发Z型RNA (Z-RNA) 积累,激活ZBP1依赖的细胞死亡. 这种机制在小细胞肺癌模型中增强了免疫治疗反应.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 支链酶体抑制剂正在作为抗癌剂进行研究.
- 目前的结合体向疗法 (STT) 通过右侧dsRNA (A-RNA) 和RIG-I类受体 (RLR) 激活抗病毒反应.
- 在了解螺旋酶体抑制剂诱导的免疫激活的替代机制方面存在差距.
研究的目的:
- 调查结合体抑制剂调节瘤微环境 (TME) 的替代机制.
- 探索左撇子dsRNA (Z-RNA) 和ZBP1在结合体抑制剂介导的抗癌作用中的作用.
- 评估ZBP1依赖性细胞死亡的潜力,作为一种加强抗性癌症免疫治疗的策略.
主要方法:
- 药理和基因抑制SF3B1活动.
- 对Z-RNA积累的分析,以应对结合酶体抑制.
- 在小鼠胚胎纤维细胞和小细胞肺癌 (SCLC) 细胞中评估ZBP1激活和ZBP1依赖细胞死亡.
- 在SCLC小鼠模型中评估免疫疗法反应,并进行结合酶体抑制.
主要成果:
- 支链酶体抑制会诱导内源Z-RNA从内部保留的RNA积累.
- Z-RNA激活ZBP1,触发纤维细胞和SCLC细胞中的细胞死亡.
- 癌症相关纤维细胞中ZBP1依赖的细胞死亡在SCLC模型中增强了免疫疗法的有效性.
结论:
- 支链酶体抑制剂可以产生Z-RNA,诱导TME中的ZBP1-依赖细胞死亡.
- 这种方法提供了一种新的治疗策略,以克服耐药性并增强癌症的免疫治疗.
- 通过结合酶体抑制向ZBP1激活,为癌症治疗提供了一个有前途的途径.
相关概念视频
RNA Splicing
60.3K
Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...
60.3K
siRNA - Small Interfering RNAs
18.4K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
18.4K
Experimental RNAi
7.3K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
7.3K
The Intrinsic Apoptotic Pathway
8.3K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
8.3K
RNA Interference
27.8K
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
27.8K
MicroRNAs
3.8K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.8K


